Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage

Journal of Infectious Diseases

Volumn 179, Issue 4, 1999, Pages 859-870

  Giorgi, Janis V ^a   Hultin, Lance E ^c   McKeating, Jane A ^c   Johnson, Timothy D ^c   Owens, Bronwyn ^b   Jacobson, Lisa P ^c   Shih, Roger ^c   Lewis, Julie ^c   Wiley, Dorothy J ^c   Phair, John P ^c   Wolinsky, Steven M ^c   Detels, Roger ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADP-RIBOSYL CYCLASE; ADULT; ANTIGENS, CD; ANTIGENS, CD38; ANTIGENS, DIFFERENTIATION; CD4 LYMPHOCYTE COUNT; HIV-1; HLA-DR ANTIGENS; HUMANS; LYMPHOCYTE ACTIVATION; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NAD+ NUCLEOSIDASE; RECEPTORS, CCR5; RECEPTORS, CXCR4; RNA, VIRAL; T-LYMPHOCYTES;

EID: 0032955651     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314660     Document Type: Article

References (74)

1. Fauci AS, Pantaleo G, Stanley S, Weissman D. Immunopathogenic mechanisms of HIV infection. Ann Intern Med 1996;124:654-63.
2. Giorgi JV. Phenotype and function of T cells in HIV disease. In: Gupta S, ed. Immunology of HIV infection. NY: Plenum Press, 1996;181-99.
3. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995;267:483-9.
4. Schuitemaker H, Koot M, Kootstra NA, et al. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T cell-tropic virus populations. J Virol 1992;66:1354-60.
5. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR. Change in coreceptor usage correlates with disease progression in HIV-1 infected individuals. J Exp Med 1997;185:621-8.
6. Scarlatti G, Tresoldi E, Bjorndal A, et al. In vivo evolution of HIV-1 coreceptor usage and sensitivity to chemokine-mediated suppression. Nat Med 1997;3:1259-65.
7. Centers for Disease Control. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR Morb Mortal Wkly Rep 1987;36:3S-14S.
8. Taylor JM, Fahey JL, Detels R, Giorgi JV. CD4 percentage, CD4 number, and CD4:CD8 ratio in HIV infection: which to choose and how to use. J Acquir Immune Defic Syndr 1989;2:114-24.
9. + T-cell number at the time of acquired immunodeficiency syndrome. Am J Epidemiol 1995;141: 645-51.
10. Schellekens PTA, Roos MTL, De Wolf F, Lange JMA, Miedema F. Low T-cell responsiveness to activation via CD3/TCR is a prognostic marker for acquired immunodeficiency syndrome (AIDS) in human immunodeficiency virus-1 (HIV-1)-infected men. J Clin Immunol 1990;10:121-7.
11. Lane HC, Depper JM, Greene WC, Whalen G, Waldmann TA, Fauci AS. Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome: evidence for a selective defect in soluble antigen recognition. N Engl J Med 1985;313:79-84.
12. Clerici M, Stocks NI, Zajac RA, et al. Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients: independence of CD4 cell numbers and clinical staging. J Clin Invest 1989;84:1892-9.
13. + T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat Med 1997;3:533-40.
14. Rosenberg ES, Billingsley JM, Caliendo AM, et al. Vigorous HIV-1 specific CD4 T cell responses associated with control of viremia. Science 1997; 278:1447-50.
15. + T cell clones during primary HIV infection. Proc Natl Acad Sci USA 1997;94:9848-53.
16. Wain-Hobson S. Virological mayhem. Nature 1995;373:102.
17. Roederer M, Dubs JG, Anderson MT, Raju PA, Herzenberg LA, Herzenberg LA. CD8 naive T cell counts decrease progressively in HIV-infected adults. J Clin Invest 1995;95:2061-6.
18. Fahey JL, Taylor JMG, Detels R, et al. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med 1990;322:166-72.
19. + T lymphocytes during HIV-1 infection. Clin Exp Immunol 1994;95:436-41.
20. + lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18:332-40.
21. + subsets in acute Epstein-Barr virus infection: comparison with chronic human immunodeficiency virus disease. J Infect Dis 1998;177:1083-7.
22. Carney WP, Iacoviello V, Hirsch MS. Functional properties of T lymphocytes and their subsets in cytomegalovirus mononucleosis. J Immunol 1983; 130:390-3.
23. + T cell activation. Clin Immunol Immunopathol 1993;67:185-91.
24. Hofmann B, Nishanian P, Baldwin RL, Insixiengmay P, Nel A, Fahey JL. HIV inhibits the early steps of lymphocyte activation, including initiation of inositol phospholipid metabolism. J Immunol 1990;145:3699-705.
25. + T cells from human immunodeficiency virus infected asymptomatic individuals. J Exp Med 1992; 175:331-40.
26. McCloskey TW, Oyaizu N, Kaplan M, Pahwa S. Expression of the Fas antigen in patients infected with human immunodeficiency virus. Cytometry 1995;22:111-4.
27. 8 cell subset in HIV disease implicate replicative senescence in HIV pathogenesis. AIDS 1996;10:F17-22.
28. + T cell turnover. Science 1996;274:1543-7.
29. Malavasi F, Funaro A, Roggero S, Horenstein A, Calosso L, Mehta K. Human CD38: a glycoprotein in search of a function. Immunol Today 1994;15:95-7.
30. Levacher M, Hulstaert F, Tallet S, Ullery S, Pocidalo JJ, Bach BA. The significance of activation markers on CD8 lymphocytes in human immunodeficiency syndrome: staging and prognostic value. Clin Exp Immunol 1992;90:376-82.
31. Prince HE, Jensen ER. Three-color cytofluorometric analysis of CD8 cell subsets in HIV-1 infection. J Acquir Immune Defic Syndr 1991;4:1227-32.
32. + cell count, soluble immune activation markers or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol 1997;16:83-92.
33. + T cells in HIV-1-infected patients. AIDS 1996;10:827-34.
34. +. J Acquir Immune Defic Syndr Hum Retrovirol 1997;15:346-55.
35. Spijkerman IJB, Prins M, Goudsmit J, et al. Early and late HIV-1 RNA level and its association with other markers and disease progression in longterm AIDS-free homosexual men. AIDS 1997;11:1383-8.
36. Richman DD, Bozzette SA. The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progession. J Infect Dis 1994;169:968-74.
37. Wolinsky SM, Korber BTM, Neumann AU, et al. Adaptive evolution of human immunodeficiency virus type 1 during the natural course of infection. Science 1996;272:537-42.
38. + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997;126:946-54.
39. Kaslow RA, Ostrow DG, Detels R, Phair JP, Polk BF, Rinaldo CR Jr. The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol 1987;126:310-8.
40. Chmiel JS, Detels R, Kaslow RA, et al. Factors associated with prevalent human immunodeficiency virus (HIV) infection in the Multicenter AIDS Cohort Study. Am J Epidemiol 1987;126:568-77.
41. Detels R, Munoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. JAMA 1998;280:1497-503.
42. Gjerset G, Nelson KA, Michael D. Methods for cryopreserving cells. In: Rose NR, deMacario EC, Fahey JL, Friedman H, Penn GM, eds. Manual of clinical laboratory immunology. 4th ed. Washington DC: American Society for Microbiology, 1992:61-7.
43. Schmid I, Uittenbogaart CH, Giorgi JV. Sensitive method for measuring apoptosis and cell surface phenotype in human thymocytes by flow cytometry. Cytometry 1994;15:12-20.
44. + cells in human immunodeficiency virus type-1 infection. Clin Immunol Immunopathol 1992;63:126-34.
45. Giorgi JV, Cheng HL, Margolick JB, et al. Quality control in the flow cytometric measurement of T-lymphocyte subsets: the Multicenter AIDS Cohort Study experience. Clin Immunol Immunopathol 1990;55:173-86.
46. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272:1167-70.
47. Deng H, Liu R, Ellmeier W, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996;381:661-6.
48. Bjorndal A, Deng H, Jansson M, et al. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J Virol 1997;71:7478-87.
49. Clapham PR, McKnight A, Weiss RA. Human immunodeficiency virus type 2 infection and fusion of CD4-negative cell lines: induction and enhancement by soluble CD4. J Virol 1992;66:3531-7.
50. Lehman EL. Nonparametrics: statistical methods based on ranks. San Francisco: Holden-Day, 1975.
51. StatXact (version 3.01). Boston: Cytel Software, 1995.
52. Muñoz A, Taylor JMG, Chmiel JS, Kingsley L, Van Raden M, Hoover DR. Estimation of time since exposure for a prevalent cohort. Stat Med 1992;11:939-52.
53. + T cell levels: results of 6 years of follow-up. J Acquir Immune Defic Syndr 1993;6:904-12.
54. + cell levels. J Infect Dis 1994;170:775-81.
55. + cells are not selectively decreased in chronic HIV disease. J Acquir Immune Defic Syndr 1994;7:665-75.
56. + cytotoxic T cells express CD38 and HLA-DR antigens. J Immunol 1993;150:3070-9.
57. + T lymphocytes as a biological calibrator. Cytometry 1998;33: 123-32.
58. + lymphocyte activity. J Infect Dis 1995;172:329-39.
59. Zack JA, Arrigo SJ, Weitsman SR, Go AS, Haislip A, Chen ISY. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 1990;61:213-22.
60. O'Brien WA, Grovit-Ferbas K, Namazi A, et al. Human immunodeficiency virus type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood 1995;86:1082-9.
61. Staprans SI, Hamilton BL, Follansbee SE, et al. Activation of virus replication after vaccination of HIV-1-infected individuals. J Exp Med 1995;182:1727-37.
62. Stanley SK, Ostrowski MA, Justement JS, et al. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med 1996;334:1222-30.
63. Bouscarat F, Levacher-Clergeot M, Dazza MC, et al. Correlation of CD8 lymphocyte activation with cellular viremia and plasma HIV RNA levels in asymptomatic patients infected by human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 1996;12:17-24.
64. Poli G, Fauci AS. Cytokine modulation of HIV expression. Semin Immunol 1993;5:165-73.
65. + T cells. Science 1995;270:1811-5.
66. Pal R, Garzino-Demo A, Markham PD, et al. Inhibition of HIV-1 infection by the β-chemokine MDC. Science 1997;278:695-8.
67. Prince HE, Kleinman S, Czaplicki C, John J, Williams AE. Interrelationships between serologic markers of immune activation and T lymphocyte subsets in HIV infection. J Acquir Immune Defic Syndr 1990;3:525-30.
68. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-6.
69. Finkel TH, Tudor-Williams G, Banda NK, et al. Apoptosis occurs predominately in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes. Nat Med 1995;1:129-34.
70. + T cell homeostasis and function in advanced HIV disease. Science 1997;277:112-6.
71. Lederman MM, Connick E, Landay A, et al. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. J Infect Dis 1998;178:70-9.
72. Fouchier RAM, Groenink M, Kootstra NA, et al. Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol 1992;66:3183-7.
73. + cell depletion and progression to AIDS. Ann Intern Med 1993;118:681-8.
74. Bleul CC, Wu L, Hoxie JA, Springer TA, Mackay CR. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci USA 1997;94:1925-30.